CytoMed Therapeutics (GDTC) Insider Kong Buys $129K of Stock
Choo Chee Kong acquired 112,000 GDTC shares in a recent transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Choo Chee Kong bought 112,000 shares of CytoMed Therapeutics Limited ($GDTC) at an average price of $1.15, worth about $128,800, on May 13, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GDTC is up 73.7% after 1 week, up 50.0% after 1 month and up 15.8% to date (from the $0.76 close on May 13, 2026).
GDTC
CytoMed Therapeutics Limited
Key Points
- Choo Chee Kong bought 112,000 shares of GDTC at $1.15 each on May 13, 2026, totaling $128,800.
- GDTC shares traded at $1.14 with no meaningful P/E ratio due to lack of profitability.
- Benchmark Co. initiated coverage on GDTC with a 'buy' rating and a $5.00 price target in July 2023.
Get $GDTC trade alerts by text
We text you when insiders, Congress or big funds trade $GDTC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated CytoMed Therapeutics Limited alert may contain errors. Disclosures
On May 13, 2026, Choo Chee Kong purchased 112,000 shares of GDTC at an average price of $1.15 per share. This transaction was valued at $128,800 and was not conducted under a pre-arranged trading plan.
Other Institutional Activity in GDTC
XTX TOPCO LTD increased its position in GDTC by 10,136 shares, ending with the same number of shares valued at $10,136. UBS GROUP AG significantly boosted its holdings, adding 5,117 shares to end with 6,182 shares worth $6,182. OSAIC HOLDINGS, INC. maintained its position with 21 shares valued at $21. Meanwhile, STONEX GROUP INC., SUSQUEHANNA INTERNATIONAL GROUP, LLP, and TWO SIGMA SECURITIES, LLC exited their positions in GDTC, each reducing their holdings to zero shares.
CytoMed Therapeutics Limited Stock Up 16.3%
GDTC shares recently traded at $1.14. The company does not have a meaningful P/E ratio since it is not currently profitable. The stock's recent trading activity and the lack of profitability suggest investors are cautious.
Insider Buying and Selling at CytoMed Therapeutics Limited
On May 13, 2026, Choo Chee Kong purchased 112,000 shares of GDTC at $1.15 each, not under a Rule 10b5-1 plan. Previously, MDR LTD sold several blocks of GDTC shares, including 117,337 shares at $1.04 on February 12, 2026, and smaller sales in 2025 at higher prices.
Analysts Set New Price Targets
Benchmark Co. initiated coverage of GDTC on July 21, 2023, with a 'buy' rating and set a price target of $5.00, indicating optimism about the company's future potential.
About GDTC
GDTC operates in a sector that was not specified in the available data. The company is involved in activities that are not detailed in the current dataset. As such, further information would be necessary to provide a comprehensive overview of its operations and market position.
Bottom Line
Choo Chee Kong's recent purchase of GDTC shares adds to the interest surrounding the company. Investors often track insider transactions like these for potential indicators of a company's future performance. However, it's important to note that insider buying or selling is just one of many factors investors consider. The information reflects past actions and may not indicate current positions.
Related Filing Alerts
Source: Choo Chee Kong's Form 4 filing on $GDTC (May 13, 2026). Find the original filing: GDTC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts